Clinical Trials Browser

Stomach Neoplasms

Glioblastoma

Stomach Neoplasms

Colorectal Neoplasms

Rectal Neoplasms

Carcinoma, Hepatocellular

Ascites, Stomach Neoplasms

Carcinoma, Hepatocellular

Stomach Neoplasms

Carcinoma, Hepatocellular

Colorectal Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Carcinoma, Digestive System Neoplasms, Cholangiocarcinoma

Nasopharyngeal Carcinoma

Advanced Biliary Tract Cancer

Carcinoma, Hepatocellular

Colorectal Neoplasms

Squamous Cell Carcinoma of Head and Neck

Nasopharyngeal Carcinoma

Breast Neoplasms

Stomach Neoplasms

Carcinoma, Hepatocellular

Biliary Tract Carcinoma

Carcinoma, Non-Small-Cell Lung

Stomach Neoplasms

Pancreatic Neoplasms, Carcinoma, Neuroendocrine

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Stomach Neoplasms

Colorectal Neoplasms

Colonic Neoplasms

PD-1 Antibody

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Carcinoma, Hepatocellular

Nasopharyngeal Carcinoma

Stomach Neoplasms

HER2-positive

Colorectal Neoplasms

Cholangiocarcinoma

Cholangiocarcinoma

Esophageal Squamous Cell Carcinoma

Uterine Cervical Neoplasms

Carcinoma, Hepatocellular

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Nonsquamous Non-Small Cell Lung Cancer

Nonsquamous Non-Small Cell Lung Cancer

Carcinoma, Hepatocellular

Clinical Trials

Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients

Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression

IMPROVE

RAIC

Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma

Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites

The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.

Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer

Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma

Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

EP-STAR

CASTLE-08

Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma

Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer

A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma

Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study

Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC

Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With Gastric Cancer

HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC

Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer

TRUMP

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy

Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma

REGSIN

A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.

Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis

FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

neoSCORE

SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC

Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC

Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

SCRCA

Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma

A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer

Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma

LM-HNSCC

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy

A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.

T-Double